| ¿µ¹® | solid tumor | ÇÑ±Û | °íÇüÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷·Î ²Ë Âù Á¾¾çÀ» ¸»ÇÔ. ¹éÇ÷º´ µîÀÇ Ç÷¾×¾Ï°ú °°ÀÌ ÇüŸ¦ ÃëÇÏÁö ¾Ê°í ¾×üÀÎ »óÅÂÀÇ ¾Ï°ú ´ëÁ¶µÇ´Â ¿ë¾î·Î¼ ´Ü´ÜÇÑ µ¢¾î¸®·Î ±¸¼ºµÈ ¾Ç¼ºÁ¾¾çÀÌ´Ù. ´ëºÎºÐÀÇ Á¾¾çÀÌ ÀÌ¿¡ ÇØ´çÇÑ´Ù. ƯÈ÷ Ç¥ÇÇÁ¶Á÷¿¡¼ ±â¿øÇÑ Á¾¾çÀ» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | ulcerating tumor | ÇÑ±Û | ±Ë¾ç¼º Á¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¾¾çÀÇ Ç¥¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇÏ´Â °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇÏ´Â °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ. |
||
| ¿µ¹® | brain tumor | ÇÑ±Û | ³úÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼ »ý±ä Á¾¾çÀ» ÁöĪÇÏ´Â ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀÎ µÎ°³°¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù. ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀÎ µÎ°³°¿¡¼ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀÎ Á¶Á÷À» ¾Ð¹ÚÇÏ°Ô µÇ°í, µÎ°³°³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Ư¡¿¡ ÀÇÇØ¼ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀÎ ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀÎ ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇÏ´Â ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù. |
||
| ¿µ¹® | epithelial tumor | ÇÑ±Û | »óÇǼºÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | Á¤»ó »ç¶÷ÀÇ Á¶Á÷Àº üǥ¸éÀ» µ¤´Â ¿ªÇÒÀ» ÇÏ´Â Á¶Á÷°ú, ÁÖ·Î ¹ß»ý±âÀÇ Á߹迱¿¡¼ ºÐÈÇÑ °£¿±Á¶Á÷¿¡¼ À¯·¡ÇÏ´Â °áÇÕÁ¶Á÷, »À, ¿¬°ñ, Áö¹æ, ±ÙÀ°, Ç÷°ü µîÀÇ Á¶Á÷ÀÇ µÎ °èÅëÀ¸·Î ³ª´ ¼ö ÀÖ´Ù. ÀüÀÚ¸¦ »óÇǼº Á¶Á÷, ÈÄÀÚ¸¦ ºñ»óÇǼº Á¶Á÷À̶ó ÇÏ¸ç ±× °¢°¢À» ±¸¼ºÇÏ´Â ¼¼Æ÷¸¦ »óÇǼº ¼¼Æ÷, ºñ»óÇǼ¼Æ÷¶ó ÃÑĪÇÑ´Ù. »óÇǼº ¼¼Æ÷¿¡¼ ±â¿øÇÏ´Â Á¾¾çÀÌ »óÇǼº Á¾¾çÀ̸ç, ±ÙóÀÇ Á¶Á÷À¸·Î ħÅõ³ª Ç÷·ù, ¸²ÇÁÀÇ Á¶Á÷À» Ÿ°í ¿ø°Å¸®ÀÇ Àå±â·Î À̵¿ÇÏÁö ¾Ê´Â ¾ç¼ºÁ¾¾ç¿¡´Â ¼±Á¾, À¯µÎÁ¾ µîÀÌ ÀÖ°í ¾ç¼º°ú ¹Ý´ë·Î ±ÙóÀÇ Á¶Á÷À¸·Î ħÅõ, ¿ø°ÝÀå±â·Î ÀüÀÌÇÏ´Â ¾Ç¼ºÁ¾¾çÀ» ¸ðµÎ ÅëĪÇÏ¿© ¾ÏÁ¾(carcinoma)À̶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | medullary tumor | ÇÑ±Û | ¼öÁú¼º Á¾¾ç |
|---|---|---|---|
| ¼³¸í | ¾ÏÀÇ º´¸®ÇÐÀûÀÎ ºÐ·ùÁß Çϳª. ¿©·¯ ±â°üÀÇ ¾Ï¿¡¼ ³ªÅ¸³ª´Âµ¥ ÁÖ·Î °©»ó»ù¾ÏÀ̳ª À¯¹æ¾Ï¿¡¼ º¸ÀδÙ. |
||
| AFP | Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
|---|---|
| BT | base of tongue; bedtime; bitemporal; bitrochanteric; bladder tumor; Blalock-Taussig [shunt]; bleedin... |
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
| TNM | primary tumor, regional nodes, metastasis [tumor staging]; thyroid node metastases; tumor node metas... |
| ADCC cell | Antibody Dependent Cellular(= Cell-Mediated) Cytotoxicity cell |
| I-CAM | Inter-Cellular-Adhesion-Molecule |
|---|---|
| ACR | Acute cellular rejection |
| ADCC | Antibody Dependent Cellular Cytotoxicity |
| ADCC | Antibody dependent cellular cytotoxic |
| Ca2+ | Cellular |
| tumor | 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant. 2. Swelling, one of the cardinal signs of inflammations, morbid enlargement. Origin: L. Tumere = to swell (12 May 1997) |
|---|---|
| tumor marker | <investigation, oncology> A substance in the body that usually indicates the presence of cancer. These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples. Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH). They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids. (18 Jul 2002) |
| tumor necrosis factor | <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin. Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine. Synonym: cachectin. Acronym: TNF (13 Nov 1997) |
| acute cellular rejection | Graft rejection which usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages which cause tissue damage. See: primary rejection. Synonym: acute rejection. (05 Mar 2000) |
| cellular | 1. Relating to, derived from, or composed of cells. 2. Having numerous compartments or interstices. Origin: L. Cellula, dim. Of cella, storeroom (05 Mar 2000) |
| cellular biology | <study> The study of cells. Implies the use of light or electron microscopic methods for the study of morphology. (18 Nov 1997) |
| cellular biophysics | Biophysics concerned with cellular processes. (05 Mar 2000) |
| cellular blue nevus | A large, acquired blue nevus in which melanocytes are often clear and large, alternating with pigmented spindle cells and which may expand deeply into the subcutis; malignant change is very rare. (05 Mar 2000) |
| cellular cartilage | An embryonic or immature stage of cartilage in which it consists chiefly of cells with very little matrix. Synonym: parenchymatous cartilage. (05 Mar 2000) |
| cellular embolism | Embolism due to a mass of cells transported from disintegrating tissue. (05 Mar 2000) |
| cellular engineering | <technique> The use of techniques for constructing replacement or additional or experimental parts of cells and tissues for both fundamental investigation and as prosthetic devices. Often involves the interfacing of cells and nonliving structures. (26 Mar 1998) |
| cellular immune theory | A concept, put forth by Elie Metchnikoff, that cells, not antibodies, were responsible for the immune response of an organism. (05 Mar 2000) |
| cellular immunity | <cell biology, immunology> Immune response that involves enhanced activity by phagocytic cells and does not imply lymphocyte involvement. Since the term is easily confused with cell-mediated immunity its use in this sense should be avoided. (26 Mar 1998) |
| cellular immunity deficiency syndrome | <syndrome> A syndrome marked by increased susceptibility to infection, especially to viral infection, associated with defective functioning of the mechanism responsible for acquired immunity of the cell-mediated kind. See: immunodeficiency. (05 Mar 2000) |
| cellular immunodeficiency with abnormal immunoglobulin synthesis | An ill-defined group of sporadic disorders of unknown cause, occurring in both males and females and associated with recurrent bacterial, fungal, protozoal, and viral infections; there is thymic hypoplasia with depressed cellular (T-lymphocyte) immunity combined with defective humoral (B-lymphocyte) immunity, although immunoglobulin levels may be normal. Synonym: Nezelof syndrome, Nezelof type of thymic alymphoplasia. (05 Mar 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|